Patient Engagement Helped Roche’s Kadcyla Get Reimbursement In Scotland
Roche has finally gained a positive recommendation from a health technology assessment body in the UK for its advanced breast cancer therapy, Kadcyla. The Scottish Medicines Consortium gave the product the all-clear after the quality-of-life benefits were highlighted by patients and doctors. It’s future in England is still unclear.
You may also be interested in...
The fund, implementing a previous election promise to improve access to drugs the NHS was not covering, became an expensive failure, report concludes. Collection of RWE in particular was a missed opportunity.
UK HTA body NICE says it is now backing Novartis’s Afinitor for the treatment of some people with advanced kidney cancer on the publicly funded National Health Service after the Swiss group offered a price discount. This changes the availability in England and Wales of the drug, which was previously only available through the controversial Cancer Drugs Fund. NICE has now given the go-ahead for routine commissioning of 13 cancer drugs/indications that were listed on the CDF before it was revamped last year.
Scottish HTA approves product following a patient committee meeting, in contrast to NICE's stance.